Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cleveland Clinic · The University of Texas MD Anderson Cancer Center · +7 more institutions
Abstract
The mean (+/- standard deviation) follow-up time was 11.1 +/- 4.4 months (median, 12.2 months). Forty-three patients (52%) had > or = five CTCs at baseline. The median PFS was 7.2 months (95% CI, 4.9 to 9.4 months), and the median OS was more than 18 months. Patients with > or = five CTCs at baseline and at first follow-up (4 weeks) had a worse prognosis than patients with less than five CTCs (baseline: median PFS, 4.9 v 9.5 months, respectively; log-rank, P = .0014; median OS, 14.2 v > 18 months, respectively; log-rank, P = .0048; first follow-up: median PFS, 2.1 v 8.9 months, respectively; log-rank, P = .0070; median OS, 11.1 v > 18 months, respectively; log-rank, P = .0029). CTCs before and after the initiation of therapy were strong, independent prognostic factors.
Detection of CTCs before initiation of first-line therapy in patients with MBC is highly predictive of PFS and OS. This technology can aid in appropriate patient stratification and design of tailored treatments.
Citation impact
- FWCI
- 19.94
- Percentile
- 100%
- References
- 23
Authors
13- MCMassimo CristofanilliCorresponding
Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Phoenix, Washington University in St. Louis, University of Michigan, Eon Corporation (United States), Michigan Center for Translational Pathology, Techtronic Industries (United States)
- DFDaniel F. Hayes
Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Phoenix, Washington University in St. Louis, University of Michigan, Eon Corporation (United States), Michigan Center for Translational Pathology, Techtronic Industries (United States)
- GTG. Thomas Budd
Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Phoenix, Washington University in St. Louis, University of Michigan, Eon Corporation (United States), Michigan Center for Translational Pathology, Techtronic Industries (United States)
- MJMathew J. Ellis
Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Phoenix, Washington University in St. Louis, University of Michigan, Eon Corporation (United States), Michigan Center for Translational Pathology, Techtronic Industries (United States)
- ASAlison Stopeck
Cleveland Clinic, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Phoenix, Washington University in St. Louis, University of Michigan, Eon Corporation (United States), Michigan Center for Translational Pathology, Techtronic Industries (United States)
Topics & keywords
- Medicine
- Metastatic breast cancer
- Internal medicine
- Circulating tumor cell
- Breast cancer
- Progression-free survival
- Oncology
- Prospective cohort study
- Good health and well-being